Completion report on merger, etc. (merger)

What happened

Completion Report on Merger, etc. 6.0 Metacare Co., Ltd. Completion Report on Merger, etc. (Merger) To: The Governor of the Financial Supervisory Service October 1, 2026 Company name: Metacare Co., Ltd. CEO: Lee Su-jin Head office location: 156 Byeongjeom-jungang-ro, Hwaseong-si, Gyeonggi-do (Tel) 02-2186-1300 (Website) http://www.meta-care.co.kr Preparer: (Title) Director (Name) Park Gon-yeong (Tel) 02-2186-1300

I. Schedule Category: Merger board resolution date; Date: 2026-07-28; Note: not applicable Category: Announcement of record date setting for shareholder determination; Date: 2026-07-28; Note: posted on the company's website Category: Material event report filing; Date: 2026-07-28; Note: not applicable Category: Merger agreement date; Date: 2026-07-29; Note: not applicable Category: Record date for determining shareholders; Date: 2026-08-12; Note: not applicable Category: Small-scale merger announcement; Date: 2026-08-12; Note: posted on the company's website Category: Period for receiving notices of objection to the merger; start date 2026-08-12; end date 2026-08-26; Note: not applicable Category: Board resolution date approving the merger; Date: 2026-08-27; Note: substitutes for a general shareholders' meeting Category: Creditor objection submission announcement; Date: 2026-08-28; Note: posted on the company's website Category: Creditor objection submission period; start date 2026-08-28; end date 2026-09-30; Note: not applicable Category: Merger effective date; Date: 2026-10-01; Note: not applicable Category: Board resolution date for the merger completion report; Date: 2026-10-01; Note: substitutes for a general shareholders' meeting Category: Merger completion report announcement; Date: 2026-10-01; Note: posted on the company's website Category: Expected merger registration date; Date: 2026-10-01; Note: not applicable ※ Since this merger is a small-scale merger under Article 527-3 of the Commercial Act, appraisal rights are not recognized, and merger approval was substituted by board of directors' approval. ※ The merger completion report meeting was substituted by an announcement procedure pursuant to a board of directors' resolution under Article 526 of the Commercial Act. ※ The expected merger registration date is the date of application for merger registration.

II. Changes in equity holdings of the largest shareholder, etc. Metacare Co., Ltd. holds 100% of the equity of JK Medi Co., Ltd., and since the merger ratio is 1:0 and this is a merger without capital increase in which no new merger shares are issued, there is no change in the equity structure of Metacare Co., Ltd. following this merger.

III. Exercise of appraisal (stock purchase) rights In the case of Metacare Co., Ltd., since the merger procedure proceeds as a small-scale merger pursuant to Article 527-3 of the Commercial Act, appraisal rights of dissenting shareholders are not recognized. In addition, in the case of the dissolving company, JK Medi Co., Ltd., since this constitutes a simplified merger by consent of all shareholders under Article 527-2 of the Commercial Act, appraisal rights are likewise not recognized for either company. Pursuant to Article 527-3 of the Commercial Act, notices of objection to the merger were received from August 12, 2026 to August 26, 2026; a total of 330 shareholders notified their objection to the merger, with the number of shares for which objection was expressed totaling 313,436 shares (1.42% of total issued shares).

IV. Matters concerning creditor protection Metacare Co., Ltd., the merging (surviving) company, issued a public notice for creditor objections (on its website) on August 28, 2026, and as of the expiration of the creditor objection submission period on September 30, 2026, no creditor submitted an objection. In addition, no decision was made to repay debts or provide substantial collateral in connection with this merger. JK Medi Co., Ltd., the merger counterparty (dissolving) company, issued a public notice for creditor objections in the Gyeonggi Ilbo on August 28, 2026, and as of the expiration of the creditor objection submission period on September 30, 2026, no creditor submitted an objection. In addition, no decision was made to repay debts or provide substantial collateral in connection with this merger.

V. Status of related litigation As of the filing date of this report, there is no litigation related to this merger that could affect the validity of the merger.

VI. Matters concerning allotment of new shares, etc. The merging (surviving) company, Metacare Co., Ltd., owns 100% of the equity of the merged (dissolving) company, JK Medi Co., Ltd., and since the merger ratio is also 1:0 for the absorption merger, Metacare Co., Ltd. will not issue new shares at the time of the merger, and there is no separate merger consideration paid in connection with the merger.

VII. Summary financial information before and after the merger, etc. (unit: KRW thousand) Category: Before merger - Metacare Co., Ltd. (surviving company); Before merger - JK Medi Co., Ltd. (dissolving company); After merger - Metacare Co., Ltd. Current assets: 11,441,679; 695,911; after merger: 12,137,590 Non-current assets: 179,999,120; 188,980; after merger: 179,828,100 Total assets: 191,440,799; 884,891; after merger: 191,965,690 Current liabilities: 63,423,005; 382,596; after merger: 63,805,601 Non-current liabilities: 487,273; not applicable; after merger: 487,273 Total liabilities: 63,910,278; 382,596; after merger: 64,292,874 Capital stock: 11,027,893; 45,000; after merger: 11,027,893 Capital surplus: 100,191,523; not applicable; after merger: 100,333,818 Retained earnings: 603,446; 457,295; after merger: 603,446 Other components of equity: 15,707,659; not applicable; after merger: 15,707,659 Total equity: 127,530,521; 502,295; after merger: 127,672,816 Total liabilities and equity: 191,440,799; 884,891; after merger: 191,965,690

※ The summary financial information above was prepared based on the separate (non-consolidated) statement of financial position as of June 30, 2026, the most recent financial statements available as of the filing date of this completion report on merger, etc., and may differ from the statement of financial position as of the merger effective date of October 1, 2026. ※ The post-merger financial statements above have not been audited (reviewed) by an external auditor and may change depending on the external auditor's audit (review).